(Reuters) A tangle of high-stakes U.S. patent disputes over COVID-19 vaccines could be tamed by court rulings or grow even more complex next year. In the headlining fight, Moderna sued Pfizer and BioNTech in August, accusing them of infringing three patents on mRNA-related innovations Moderna said it developed before the COVID-19 pandemic. Pfizer and BioNTech responded earlier this month that Moderna had overstated its contributions to the field of mRNA technology. They asked a Massachusetts federal court to declare Moderna’s patents in the lawsuit invalid and dismiss the case.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.